share_log

醫思健康：截至2024年1月31止月份之股份發行人的證券變動月報表

EC HEALTHCARE: Monthly Return of Equity Issuer on Movements in Securities Ended 31 January 2024

香港交易所 ·  Feb 6 19:53
Summary by Futu AI
醫思健康（EC HEALTHCARE）於2024年2月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年1月31日的情況。報告顯示，公司的法定/註冊股本維持不變，總額為380,000港元。在股份期權方面，根據2016年2月19日通過的購股權計劃，本月內有3,450,000股份期權失效，使得本月底結存的股份期權數目減至22,262,500。此外，報告還包括了OrbiMed認股權證和GS可換股債券的詳細資料，其中OrbiMed認股權證將於2026年2月5日到期，而GS可換股債券則於同年2月5日到期，本金總額分別為36,400,000港元和234,000,000港元。報告最後確認，所有證券發行均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
醫思健康（EC HEALTHCARE）於2024年2月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年1月31日的情況。報告顯示，公司的法定/註冊股本維持不變，總額為380,000港元。在股份期權方面，根據2016年2月19日通過的購股權計劃，本月內有3,450,000股份期權失效，使得本月底結存的股份期權數目減至22,262,500。此外，報告還包括了OrbiMed認股權證和GS可換股債券的詳細資料，其中OrbiMed認股權證將於2026年2月5日到期，而GS可換股債券則於同年2月5日到期，本金總額分別為36,400,000港元和234,000,000港元。報告最後確認，所有證券發行均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
EC HEALTHCARE SUBMITTED ITS LATEST SECURITIES MONTHLY CHANGE REPORT TO HONG KONG TRADING AND SETTLEMENT LIMITED ON 6 FEBRUARY 2024, COVERING THE SITUATION AS OF 31 JANUARY 2024. The report showed that the company's regulated/registered share capital remained unchanged, totalling HK$380,000. In terms of stock options, 3,450,000 share options expired this month under the share option plan approved on February 19, 2016, reducing the number of stock options outstanding at the end of the month to 22,262,500. In addition, the report includes details of the OrbiMed warrants and GS convertible bonds, where the OrbiMed warrants mature on February 5, 2026, and the GS convertible notes mature on February 5 of the same year, totaling HK$36,400,000 and HK$234,000,000, respectively. The report finally confirms that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
EC HEALTHCARE SUBMITTED ITS LATEST SECURITIES MONTHLY CHANGE REPORT TO HONG KONG TRADING AND SETTLEMENT LIMITED ON 6 FEBRUARY 2024, COVERING THE SITUATION AS OF 31 JANUARY 2024. The report showed that the company's regulated/registered share capital remained unchanged, totalling HK$380,000. In terms of stock options, 3,450,000 share options expired this month under the share option plan approved on February 19, 2016, reducing the number of stock options outstanding at the end of the month to 22,262,500. In addition, the report includes details of the OrbiMed warrants and GS convertible bonds, where the OrbiMed warrants mature on February 5, 2026, and the GS convertible notes mature on February 5 of the same year, totaling HK$36,400,000 and HK$234,000,000, respectively. The report finally confirms that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.